Partnership between Ligand Pharmaceuticals and Agenus

Ligand Pharmaceuticals shared on their LinkedIn page:

“We are excited to announce our latest royalty monetization with Agenus. This partnership gives Ligand an interest in multiple oncology products diversified across different targets and indications.

Our investment team spent a significant amount of time and effort conducting diligence on each of these unique and valuable assets and we are enthusiastic about the potential of Agenus’ partnered portfolio and the company’s broad and highly differentiated botensilimab and balstilimab (BOT/BAL) clinical development program.

Under the terms of the agreement, Ligand is entitled to receive royalties and milestone payments on six Agenus-partnered oncology programs and royalties on future global net sales generated by BOT/BAL.

This partnership will support Agenus’ planned confirmatory Phase 3 trial in its lead indication of patients with metastatic, relapsed/refractory colorectal cancer not microsatellite instability-high or deficient mismatch repair, who are without active liver metastases, which received Fast Track Designation from the FDA in April 2023.

Read the announcement here.”

Source: Ligand Pharmaceuticals/LinkedIn